Abstract
The Enhancing NeuroImaging Genetics through Meta-Analysis (ENIGMA) Consortium is a collaborative network of researchers working together on a range of large-scale studies that integrate data from 70 institutions worldwide. Organized into Working Groups that tackle questions in neuroscience, genetics, and medicine, ENIGMA studies have analyzed neuroimaging data from over 12,826 subjects. In addition, data from 12,171 individuals were provided by the CHARGE consortium for replication of findings, in a total of 24,997 subjects. By meta-analyzing results from many sites, ENIGMA has detected factors that affect the brain that no individual site could detect on its own, and that require larger numbers of subjects than any individual neuroimaging study has currently collected. ENIGMA’s first project was a genome-wide association study identifying common variants in the genome associated with hippocampal volume or intracranial volume. Continuing work is exploring genetic associations with subcortical volumes (ENIGMA2) and white matter microstructure (ENIGMA-DTI). Working groups also focus on understanding how schizophrenia, bipolar illness, major depression and attention deficit/hyperactivity disorder (ADHD) affect the brain. We review the current progress of the ENIGMA Consortium, along with challenges and unexpected discoveries made on the way.
Highlights
Origins of brain imaging in human populationsDuring the “Decade of the Brain” in the 1990s (Jones and Mendell 1999), a number of major neuroimaging centers began to scan hundreds of patients and healthy individualsO
The Enhancing NeuroImaging Genetics through Meta-Analysis (ENIGMA) Consortium is a collaborative network of researchers working together on a range of largescale studies that integrate data from 70 institutions worldwide
We review the current progress of the ENIGMA Consortium, along with challenges and unexpected discoveries made on the way
Summary
During the “Decade of the Brain” in the 1990s (Jones and Mendell 1999), a number of major neuroimaging centers began to scan hundreds of patients and healthy individuals. X. Liu Taub Institute for Research on Alzheimer Disease and the Aging Brain, Columbia University Medical Center, New York, NY, USA. K. van Eijk Department of Psychiatry, Rudolf Magnus Institute, University Medical Center Utrecht, Utrecht, The Netherlands some functional measures, and even brain metabolites (Batouli et al 2012)—could be explained by genetic relationships among individuals. Measures of brain volume, integrity, receptor distribution, or chemical composition, might be more directly related to the function of genes—both genes whose function is unknown, and known candidate genes—such as growth factors, transcription factors, guidance molecules, or neurotransmitters and their transporters Many of these had already been implicated in the risk for psychiatric illness, and imaging offered the opportunity to study differences in brain connectivity or function, in carriers of genetic variants associated with disease risk.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
